Pulmonary Hypertension
Congress Materials – The Professional Society for Health Economics and Outcomes Research (ISPOR 2025)
2025 The Professional Society for Health Economics and Outcomes Research | May 13-16 | Montreal, QC, Canada
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Budget Impact Analysis of Introducing OPSYNVI for the Treatment of Adult Patients Diagnosed with Pulmonary Arterial Hypertension
Paoli C, Agarwal A, Ngantung W, Saeedian M
Medical costs in patients with pulmonary arterial hypertension (PAH) on oral triple therapy including selexipag in the United States (US): A retrospective claims-based study
Carly J Worden, Yuen Tsang, Louise Huafeng Yu, Ambika Satija, Marjolaine Gauthier-Loiselle
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.